Talimogene, nivolumab, and trabectedin for advanced sarcoma
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign informed consent.
- You have sarcoma that is locally advanced and not removable by surgery or is metastatic, and it can include desmoid tumor or chordoma.
- You have measurable tumors and at least one accessible tumor site that doctors can inject.
- Your general health is good enough (ECOG 0–1) and you’re expected to live at least 3 months.
- Your blood counts, liver, and kidney tests are within required ranges.
- You can follow the study plan for visits, injections, and safety rules (including pregnancy prevention rules if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
This trial tests a combination of paclitaxel polymer micelles with other drugs for people with advanced bone or soft tissue sarcoma that has worsened after first-line chemotherapy. The goal is to see if this new formulation can help shrink tumors or slow their growth.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This trial tests a combination of two drugs, palbociclib and pembrolizumab, in people with certain types of advanced sarcoma (cancer of the soft tissues) that have continued to grow despite prior treatment. It aims to see if this combination can shrink tumors or slow down the cancer.
This trial tests whether giving pembrolizumab along with chemotherapy delivered directly into an arm or leg (isolated limb infusion) can shrink sarcoma tumors. It is for people with advanced or metastatic sarcoma in an arm or leg who can safely have this local treatment.
This Phase 2 study tests whether selumetinib and durvalumab can slow or shrink certain advanced sarcomas. It’s for adults with disease that has come back, progressed, or can’t be safely removed with surgery.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.